Neurofilament as a Surrogate Endpoint Goes on Trial in Tofersen Adcomm

Biomarkers as a surrogate endpoint in ALS will go on trial on March 22 as Biogen and Ionis’s tofersen faces the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee.